DOI: https://doi.org/10.26641/2307-5279.23.4.2019.187164

Comparative analysis of the rate of infection of genital excreta and intraoperatively removed prostatic tissue by sexually transmitted pathogens in patients with benign prostatic hyperplasia

S.P. Pasiechnikov, V.S. Hrytsai, Y.M. Klymenko, A.V. Kravchenko

Abstract


The study realizes a comparative evaluation of sexually transmitted pathogens infection, according to the study of genital excreta and intraoperatively removed prostatic tissue of 195 patients with benign prostatic hyperplasia, who underwent transvesical prostatectomy.

The obtained results state that the rate of infection by STDs of the patients with BPH who are admitted to the hospital for planned prostatectomy is 47.7%. The total frequency of detected DNA pathogens of STDs by PCR was significantly higher almost 1.4 times in genital excreta than in intraoperatively removed prostatic tissue.

The dominant pathogens of STDs in the genital excreta are the mollicutes, while in the intraoperatively removed prostate tissue, Trichomonas vaginalis prevails. The discrepancy between the results of the study of genital excreta and intraoperatively removed prostate tissue in infected patients with BPH was 84.9%, and 14% of infected patients with BPH was detected with a study of prostate tissue, which makes it appropriate to provide specific treatment for the prevention of postoperative complications.

Keywords


benign prostatic hyperplasia; infection by STD pathogens; genital excreta; intraoperatively removed prostatic tissue

References


Возіанов О.Ф., Пасєчніков С.П., Павлова Л.П. Досягнення й проблеми урологічної допомоги населенню України. Урологія. 2001. № 4. С. 3–6.

Guess H.A., Chute C.G., Garraway W.M. et al. Similar levels of urological symptoms have similar impact on Scottish and American men-althuogh Scots report less symptoms. J. Urol. 1993. Vol. 150. P. 1701–1705.

Cтаховский Э.А., Билык В.И., Войленко О.А., Котов В.А. Диагностика доброкачественной гиперплазии предстательной железы. Журнал практичного лікаря. 2001. № 6. С. 29–31.

Alcaraz A., Hammerer P., Tubaro A. et al. Is there evidence of a relationship between prostatic hyperplasia and prostate cancer? Findings of literature review. Eur Urol. 2009. Vol. 55. P. 864–875. doi:10.1016/j.eururo.2008.11.011.

Lepor H. Pathophsiology of benign prostatic hyperplasia in the aging male population. Rev Urol. 2005. Vol. 7. P. 3–7.

Hsing A.W., Chokkalingam A.P. Prostate cancer epidemiology. Front Biosci. 2006. Vol. 11. P. 1388–1413.

Ries L.G., Melbert D., Krapcho M. et al. Cancer Statistics Review, 1975–2004. Bethesda: National Cancer Institute, 2007.

Platz E.A., De Marzo A.M. Epidemiology of inflammation and prostate cancer. J. Urol. 2004. Vol. 171. P. 36–40.

Переверзев А.С. Воспаление и рак простаты. Урология. 2011. № 4(59). С. 59–69.

Перевєрзєв А.С. Роль хронічного простатиту в патогенезі рака передміхурової залози. Онкоурологія. 2011. № 2. С. 12–17.

Imyationov E.N., Togo A.V., Hanson K.P. Searching for cancer-associated gene polymorphisms: promises and obstscl. Cancer Lett. 2004. Vol. 204. P. 3–14.

Palapattu G., Sutchiffe S., Bastian P. et al. Prostate carcinogenesis and inflammation: emerging insights. Cancerogenesis. 2004. Vol. 26. P. 1117–1181.

Nickel J.C. Prostatic inflammation in benign prostatic hyperplasia – the third component? Can. J. Urol. 1994. Vol. 1. P. 1–4.

Nickel J.C., Roehrborn C.G. Optimizing the management of prostate diseases: prostatitis and benign prostatic hyperplasia. BJU. Int. 2008. Vol. 101. P. 1–30.

Lucia M.S., Epstein J.I., Goodman P.J. et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 2007. Vol. 99. P. 1375–1382.

Thompson I.M., Tangen C.M., Goodman P.J. et al. Long-Term Survival of Participants in the Prostate Cancer Prevention Trial. N. Engl. J. Med. 2013. Vol. 369. P. 603–610.

Gregoire R., Aurelien D., Yves A. et al. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur. Urol. 2009. Vol. 8. P. 879–886.

Di Silverio F., Gentile V., Dematteis A. et al. Distribution inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur. Urol. 2003. Vol. 43. P. 164–175.

Горпинченко И.И., Добровольская Л.И. Хламидийная инфекция у больных с воспалительными заболеваниями половых органов. Лікарська справа. 1997. № 5. С. 99–104.

Gardner W., Culberson D., Bennett B. Trichomonas vaginalis in the prostate gland. Arch. Pathol. Lab. Med. 1986. Vol. 110. P. 430–432.

Krieger J.N., Rein M.F. Zinc sensitivity of Trichomonas vaginalis: in vitro studies and clinical implications. J. Infect Dis. 1982. Vol. 146. P. 341–345.

Kuberski T. Trichomonas vaginalis associated with nongonococcal urethritis and prostatitis. Sex Transm Dis. 1980. Vol. 7. P. 135–136.

Kurnatowska A., Kurnatowski A., Mazurek L., Wedzikowski P. Rare cases of prostatitis caused by invasion of Trichomonas vaginalis with Candida albicans. Wiad. Parazytol. 1990. Vol. 36. P. 229–236.

Abdelatif O.M., Chandler F.W., Jr. McGuire B.S. Chlamydia trachomatis in chronic abecterial prostatitis: demonstration of calometric in situ hybridization. Hum. Pathol. 1991. Vol. 22. P. 41–44.

Bruce A.W., Reid G. Prostatitis associated with Chlamydia trachomatis in 6 patients. J. Urol. 1989. Vol. 142. P. 1006–1007.

Bruce A.W., Chadwick P., Willett W.S., O’Shaughnessy M. The role of chlamydiae in genitourinary disease. J.Urol. 1981. Vol. 126(5). P. 625–629.

Chiarini F., Mansi P., Tamao V., Gentile F. et al. Chlamydia trachomatis genitourinaryinfections: laboratory diagnosis and therapeutic aspects. Evaluation of invitro and in vivo effectiveness of azithromycin. J.Chemother. 1994. Vol. 6. P. 238–242.

Brunner H., Weidner W., Schiefer H.G. Studies on the role of Ureaplasma urealyticum and Mycoplasma hominis in prostatitis. J. Infect. Dis. 1983. Vol. 147(5). P. 807–813.

Weidner W., Brunner H., Krause W. Quantitative culture of Ureaplasma urealyticum in patients with chronic prostatitis or prostatosis. J. Urol. 1980. Vol. 124. P. 622–625.

Benson P.J., Smith C.S. Cytomegalovirus prostatitis. J. Urol. 1992. Vol. 40(2). P. 165–167.

Doblе A., Harris J.R., Robinson T. Prostatodynia and herpes simplex virus infection. J. Urol. 1991. Vol. 38. P. 247–248.

Пасечников С.П., Митченко Н.В., Грицай В.С. Инфицированность больных гиперплазией предстательной железы возбудителями заболеваний, передающихся половым путём. Здоровье мужчины. 2006. № 2. С. 203–205.

Возіанов О.Ф., Пасєчніков С.П., Мітченко М.В., Грицай В.С., Литвиненко Р.А. Особливості інфікованості хворих на доброякісну гіперплазію передміхурової залози, ускладнену гострою затримкою сечі. Урологія. 2010. Т. 14. С. 80–84.

Пасєчніков С.П., Грицай В.С., Литвиненко Р.А., Глєбов А.С. Визначення впливу інфікованості Trichomonas Vaginalis на розвиток запального процесу в тканині передміхурової залози та результати оперативного лікування хворих на доброякісну гіперплазію передміхурової залози. Урологія. 2013. № 2(65). С. 46–50.